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Abstract
Many products of lipid oxidation have been associated with human diseases. These include F2-isoprostanes (F2-
IsoPs), hydroxyeicosatetraenoic acid products (HETEs), and cholesterol oxidation products (COPs). Here we
present measurements of F2-IsoPs, HETEs, COPs, and arachidonate in single plasma samples of patients with
acute (dengue fever and ischemic stroke) and chronic (Parkinson’s) diseases, and in age-matched study con-
trols. Urine samples were collected for F2-IsoPs analysis. Our analysis demonstrated elevated F2-IsoPs levels in
ischemic stroke, HETEs in Parkinson’s disease, dengue fever, and ischemic stroke, and COPs in Parkinson’s
disease and dengue fever patients, as compared with those in age-matched study controls. Strong but complex
correlations were observed between levels of certain oxidized lipid products and age. The relations between
various oxidized lipids and dengue fever, stroke, and Parkinson’s disease are discussed in relation to the se-
lection and application of biomarkers of oxidative lipid damage, in particular the need for corrections for age
and lipid levels. Antioxid. Redox Signal. 11, 407–420.
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Introduction
MEASUREMENT of oxidized lipids has become increasinglyimportant to help in understanding the dynamics of
oxidative stress in human diseases. For example, F2-iso-
prostanes (F2-IsoPs) are a group of metabolites (64 regioiso-
mers) produced by nonenzymatic free radical oxidation of
arachidonic acid. Some F2-IsoPs are potent vasoconstrictors
that may be involved in the pathology of stroke, diabetes
mellitus, and atherosclerosis (2, 26, 28). Arachidonic acid also
can be oxidized by free radicals, lipoxygenases, and cy-
tochrome P450 enzymes to produce epoxyeicosatrienoic acid
products (EETs) or hydroxyeicosatetraenoic acid products
(HETEs) (8, 13, 48, 54). Although different types of HETE iso-
mers have been described (such as 5-, 8-, 9-, 11-, 12-, 15-, 20-
HETE), the precise roles of these isomers in vivo are poorly
understood. Recently some of these isomers have been linked
with vascular function and cancer [e.g., 20-HETE is reported
to be a vasoconstrictor in the cerebral circulation (39); in-
creased 9-HETE was observed in coronary artery disease
(41); and 5-, 8-, 12-, and 15-HETE are involved in tumor de-
velopment (35)].
Another group of oxidized lipids that has drawn interest is
the cholesterol oxidation products (COPs). Cholesterol can be
oxidized via enzymatic P450 reactions to give 7-, 24-, 
25-, and 27-hydroxycholesterol or by nonenzymatic free radi-
cal reactions to give 7-hydroxycholesterol and 7-ketocholes-
terol (7). Some COPs can be formed by both pathways (e.g.,
7-hydroxycholesterol is formed as a precursor to bile syn-
thesis and also by free radical attack). COPs are found in dif-
ferent forms (esterified, sulfated, conjugated, and free in vivo)
(7), and some of the COPs appear to be specific to certain dis-
ease models. For example, 24- and 27-hydroxycholesterol are
proposed to be involved in brain vascular function (4), and oth-
ers have suggested a role of COPs in coronary artery diseases
and in the development of dementia and stroke (37).
Simultaneous measurement of different lipid oxidation
products may allow a better understanding of the signifi-
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cance of these molecules with respect to human diseases (2,
14, 15, 22, 30). Our group has previously reported techniques
for the measurement of multiple oxidation products of
arachidonic acid and cholesterol in a single plasma sample
(22). Such a method is valuable, first because clinical sam-
ples are often limited. Second, the stated levels, and ranges
of levels, of various biomarkers vary between laboratories,
many depending on the exact analytic method applied, and
so it is often difficult to compare clinical disease sample re-
sults between different published reports. In this study, by
using a standardized analytical protocol, we measured a
range of oxidized lipid biomarkers (F2-IsoPs, HETEs, COPs)
in body fluids from patients with acute (dengue fever or isch-
emic stroke) and chronic (Parkinson’s disease) diseases, and
study controls. Our findings provide further insight into the
relation between lipid oxidation products and human dis-
eases, and emphasize the careful controls that are needed
when measuring such products and presenting the data.
Materials and Methods
Materials
High purity grade (95%) heavy labeled standards of F2-
isoprostanes (F2-IsoPs), 8-iso-PGF2-d4, IPF2-VI-d4, and
IPF2-IV-d4, hydroxyeicosatetraenoic acid (HETEs) stan-
dards, 5(S)-HETE-d8, 12(S)-HETE-d8, 15(S)-HETE-d8, 20-
HETE-d6, and arachidonic acid-d8 were obtained from Cay-
man Chemicals, (Ann Arbor, MI). Oxysterol standards
(purity 95%), 7-OH cholesterol-d7, 7-OH cholesterol-d7,
26 (27)-OH cholesterol-d5, and 7-keto-cholesterol-d7, were
purchased from CDN Isotopes, Canada, and 24-OH choles-
terol-d7, from Medical Isotopes Inc. (Pelham, NH).
Analytic grade formic acid was purchased from Lancaster
(England), ammonium hydroxide, potassium hydroxide,
butylated hydroxytoluene (BHT), hydrochloric acid, ethanol,
acetic acid from Merck (Darmstadt, Germany), and hexane
from Tedia (Fairfield, OH). HPLC-grade methanol was pur-
chased from EM Science (Darmstadt, Germany), and iso-
octane and ethyl acetate, from Fisher Scientific (UK). N,O-
bis(trimethylsilyl)trifluoroacetamide  1% trimethylchloro-
silane (BSTFA  TMCS) silylating agent was obtained from
Pierce Chemicals (Rockford, IL). Pentafluorobenzylbromide
(PFBBr) and N,N-diisopropylethylamine (DIPEA) were pur-
chased from Sigma Chemicals (St. Louis, MO). Oasis Mixed
Anion Exchange (MAX) cartridges for solid-phase extraction
(SPE) were from Waters Corp. (Milford, MA).
Study design and patients
The study was carried out in a single center (Clinical Trial
Unit, National University Hospital, Singapore), where selec-
tion of healthy controls was randomized. For Parkinson’s
disease, dengue fever, and stroke it was designed as an age-
matched case–control study. The gender ratio (male/female)
for healthy controls and Parkinson disease patients was 1:1,
whereas for dengue fever and stroke patients, it was 1:2. No
restriction was placed on the diet of the healthy control and
the recruited patients (except to exclude the use of dietary
supplements), but where possible, all were asked to fast
overnight before blood and urine sampling to minimize any
absorption of COPs or other oxidized lipid products (50). We
included patients with Parkinson’s disease, ischemic stroke,
and dengue infection from the National University Hospi-
tal, Singapore. All patients provided informed consent be-
fore recruitment to the study. Acute ischemic stroke was di-
agnosed clinically and supported by neuroimaging
modalities such as computed tomography and magnetic res-
onance imaging. We included patients with first-ever stroke
with a National Institute of Health Stroke Severity (NIHSS)
score exceeding 6 who were seen within 24 h from the on-
set of their symptoms. Acute dengue infection was diag-
nosed in patients who manifested a fourfold increase in IgG
antibodies against dengue, measured in acute and convales-
cent sera. Parkinson’s disease was diagnosed in patients who
fulfilled the United Kingdom Parkinson’s Disease Society
Brain Bank criteria in the presence of bradykinesia and at
least one of the following: muscular rigidity, rest tremor, pos-
tural instability unrelated to primary visual, cerebellar,
vestibular, or proprioceptive dysfunction. We recruited
healthy controls who did not smoke and who were not tak-
ing any medications or dietary supplements. The study pro-
tocol was approved by the Institutional Review Board of the
National University Hospital.
Sample preparation
Samples of blood and urine of healthy volunteers and
Parkinson disease patients were collected in the morning. As
for dengue fever and ischemic stroke patients, blood and
urine samples were taken on the day of clinical diagnosis be-
fore any clinical intervention and also (where possible) after
recovery. Venous blood was collected into Na-EDTA blood
tubes that were primed with 15 l of 5 mM indomethacin
dissolved in ethanol. Plasma was separated immediately by
centrifugation and then placed into tubes with 20 l/ml
plasma of 2 mM BHT (in ethanol). The samples were stored
at 80°C and were analyzed within 6 months of sample col-
lection.
Before analysis, the plasma samples were thawed at room
temperature. Mixed heavy isotopes, 8-iso-PGF2-d4, IPF2-
VI-d4, 5(S)-HETE-d8, 12(S)-HETE-d8, 15(S)-HETE-d8, 20-
HETE-d6 and arachidonic acid-d8, and 7-OH cholesterol-d7,
7-OH cholesterol-d7, 24-OH cholesterol-d7, and 26 (27)-OH
cholesterol-d5, and 7-keto-cholesterol-d7, all prepared in eth-
anol, were added to plasma and mixed. To measure (22) the
total (freeesterified) form of oxidized lipids (F2-IsoPs,
HETEs, and COPs) and total arachidonate, 1 ml plasma was
hydrolyzed at 37°C for 30 min with 1 ml of 1 M potassium
hydroxide prepared in methanol for the release of esterified
lipids. Afterwards, 0.5 ml methanol, 0.2 ml of 5 M HCl, and
2.5 ml of 40 mM formic acid (pH 4.6) were further added
and mixed. For measurement of free forms in plasma and
urine (22, 23) for F2-IsoPs and in plasma for HETEs, 1 ml of
formic acid (40 mM, pH 4.5) was added to 1 ml of sample,
mixed and then immediately processed by SPE. For stan-
dardizing the dilution of urine, creatinine levels were mea-
sured by using Sigma Diagnostic kit (St. Louis, MO), and to-
tal cholesterol levels, by the National Referral Laboratory
(NRL), Singapore.
Extraction and derivatization of oxidised lipid products
The prepared samples were extracted and derivatized by
using a previously described method (22). In brief, MAX SPE
cartridges were used to purify the prepared samples, by
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washing with 2 ml of 2% ammonium hydroxide and then by
2 ml of methanol: 20 mM formic acid (pH 4.6) mix (40:60
vol/vol). Afterward, different solvents were sequentially
added for the elution of COPs, and F2-IsoPs, HETEs, and
arachidonate. COPs were eluted with 2 ml of hexane fol-
lowed by 2 ml of hexane:ethyl acetate (70:30 vol/vol). The
two fractions were combined for derivatization for GC-MS
analysis. Thereafter, total F2-IsoPs, total HETEs, and total
arachidonate were eluted with 2 ml of hexane/ethanol/
acetic acid (20:29.4:0.6 vol/vol). The procedure described
was repeated for extraction of free F2-IsoPs and HETEs in
plasma and urine.
The collected samples were completely dried under ul-
tra–high-purity nitrogen gas. Samples for COPs measure-
ment were derivatized with 50 l pyridine and 50 l 
N,O-bis(trimethylsilyl)trifluoroacetamide with 1% trime-
thylchlorosilane (BSTFA  1% TMCS) and incubated for 2 h
at room temperature. The derivatized mix was then dried
and reconstituted in 30 l undecane with 5 l BSTFA 
1%TMCS before GC-MS analysis. Samples for total F2-IsoPs,
total HETEs and total arachidonate measurement were de-
rivatized with 15 l DIPEA (10% vol/vol acetonitrile) and
30 l PFBBr (10% vol/vol acetonitrile) at room temperature
for 30 min and dried under nitrogen gas. Acetonitrile (20 l)
and BSTFA with 1% TMCS (40 l) were then added and in-
cubated at room temperature for 2 h. The derivatized sam-
ples were then dried and reconstituted in 70 l iso-octane
and incubated at room temperature for 20 min. Before GC-
MS analysis, an aliquot of 5 l of the sample was taken into
another vial and diluted with 195 l of iso-octane for total
arachidonate measurement, and the rest was used to mea-
sure total F2-IsoPs and total HETEs. 
Analysis with gas chromatography–mass 
selective detection
F2-IsoPs, HETEs, and arachidonate. The derivatized sam-
ples for F2-IsoPs, HETEs, and arachidonate were analyzed
with a mass selective detector (Hewlett-Packard 5973N; Ag-
ilent Technologies,) connected to a gas chromatograph
(Hewlett-Packard 6890; Agilent Technologies, Santa Clara,
CA), fitted with an automatic sampler and a computer work-
station. The temperature settings were programmed (22).
The mass spectrometer was used in the negative chemical
ionization (NCI) mode set at selective ion monitoring (SIM),
and chromatographic separations were carried out on a
fused silica capillary column coated with cross-linked 5%
phenylmethylsiloxane (HP-5; Agilent Technologies). Quan-
titation was achieved by relating the peak area of the total
and free forms of F2-IsoPs or HETEs, and total arachidonate
with their respective deuterated internal standard peaks (22).
Cholesterol oxidation products. For measurement of COPs,
a mass selective detector (Hewlett-Packard 5975; Agilent
Technologies) interfaced with a gas chromatograph (Hewlett-
Packard 5890 II) and equipped with an automatic sampler
and a computer workstation was used. Separations were car-
ried out on a fused silica capillary column coated with cross-
linked 5% phenylmethylsiloxane (Ultra 2, Agilent Technolo-
gies), and the temperature settings were programmed (22).
The detector was set at electron ionization (EI) mode, and
measurement was performed by SIM. Quantification of COPs
was calculated by comparing peak area of each compound
with the deuterated internal heavy standard.
Statistical analysis
All analysis was performed by using GraphPad Prism ver-
sion 5.0 for Macintosh (GraphPad Software, San Diego, CA).
Student’s t test was performed between healthy subjects and
for all illnesses. The significance of onset to recovery stage
for dengue and stroke patients was tested with analysis of
variance at confidence level of 95%. Spearman’s ranked cor-
relation was performed between age and F2-IsoPs, HETEs,
arachidonate, and COPs, and Pearson’s correlation, between
urinary F2-IsoPs, plasma F2-IsoPs, and arachidonate at 95%
confidence interval.
Results
The purpose of this article is to examine the levels of var-
ious oxidized lipid biomarkers in healthy controls and pa-
tients with examples of acute diseases (dengue fever and
recent-onset ischemic stroke) and a chronic disease (Parkin-
son’s disease). All these diseases are complex and multifac-
torial, which must be borne in mind when evaluating the re-
sults.
Before beginning studies on clinical samples, we deter-
mined whether age or gender affects levels of F2-IsoPs,
arachidonate, and COPs (Fig. 1, Tables 1 and 2) in healthy
controls. No significant gender effects were found (data not
shown). The data for plasma arachidonate and cholesterol
were initially ranked according to age, and Spearman’s cor-
relation study was performed for every 5-year increment
starting from 25 years. Graphic linear regression and corre-
lation significance was found to change at 50  5 years.
Hence the data are presented as three groups, all (25–86
years), younger than 50 years (25–49 years), and 50 years and
older (50–86 years). A significant positive correlation was
found between urinary F2-IsoPs and age (Fig. 1). This corre-
lation was observed in the age range 25–49 years but not in
the range from 50 to 86 years. By contrast, little correlation
was shown between plasma total, esterified, and free F2-
IsoPs and age (Table 1). After arachidonate adjustment of the
data, plasma total and esterified F2-IsoPs still showed only
a weak correlation with age (Table 1). Significant negative
correlations between age (25–86 years) and plasma arachi-
donate, total cholesterol, 7-hydroxycholesterol, and 27-hy-
droxycholesterol were demonstrated (Fig. 1 and Table 2), but
in this case, the decrease for all four biomarkers was much
more obvious in the subjects aged 50 or older (Fig. 1 and
Table 2). Significant negative correlations for 7-hydroxyc-
holesterol, 24-hydroxycholesterol, and 27-hydroxycholes-
terol with age (25–86 years) were seen even after adjustment
for total cholesterol (Table 2). The decrease was noticeable
in 50-aged subjects for 24-hydroxycholesterol and subjects
younger than 50 years for 27-hydroxycholesterol.
These data illustrate the importance of careful age match-
ing of groups when performing clinical studies. Thus we
eliminated data for healthy subjects younger than 40 years
for comparison with the acute and chronic disease patients,
in whom the median age was 56 years, and range, 40–69
years. No gender difference was found in the level of the ox-
idized lipids measured in the age-matched control groups
and disease patients. Our correlation analysis also showed
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plasma total F2-IsoPs to be positively correlated with plasma
arachidonate and urinary F2-IsoPs levels (Fig. 2) over the
whole age range.
F2-isoprostanes and arachidonate in disease
Plasma F2-IsoPs levels (total, esterified, or free) of Parkin-
son’s disease subjects showed no significant difference from
healthy age-matched controls (Fig. 3). It should be noted that
these patients were being treated with various drugs (e.g., L-
DOPA), which could perhaps have pro- and antioxidant
properties against lipid peroxidation (1, 14, 33, 42, 43). Un-
like for normal controls, a significant positive correlation was
found for Parkinson’s disease between age and plasma total
F2-IsoPs (r  0.52; p  0.01). Correlations also were noted be-
tween urinary F2-IsoPs and age (r  0.41; p  0.05), between
plasma total F2-IsoPs and arachidonate (r  0.67; p  0.001),
and between urinary F2-IsoPs and plasma free F2-IsoPs (r 
0.41; p  0.05), but this did not cause F2-IsoPs levels to be-
come significantly greater than those in normal controls.
Parkinson’s disease did not change arachidonate levels com-
pared with those in healthy controls (Fig. 3). Analysis of the
age-matched controls (40–69 years) did not show any sig-
nificant correlation between age, F2-IsoPs, HETEs, arachido-
nate, and COPs, and between urinary F2-IsoPs and plasma
F2-IsoPs.
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FIG. 1. Spearman’s correlation of ox-
idized lipid products in plasma of
healthy controls. (A) Arachidonate vs.
age [25–86 years (y); n  81]. (B) Arachi-
donate vs. age younger than 50 y (25–49
y; n  40). (C) Arachidonate vs. age 50
y and older (50–86 y; n  41). (D) Uri-
nary F2-IsoPs vs. age (25–86 y; n  92).
(E) Urinary F2-IsoPs vs. age younger
than 50 y (25–49 y; n  52). (F) Urinary
F2-IsoPs vs. age 50 y and older (50–86
y; n  40). Mean  SEM at 95% confi-
dence level for each correlation is indi-
cated by dotted line. ALL indicates all
subjects.
By contrast, F2-IsoPs (total, esterified, adjusted for
arachidonate, and urinary) levels were significantly higher
than those in age-matched controls during the first 24 h of
acute stroke (onset) and tended to be higher even after re-
covery from stroke (Fig. 3). Onset in this context means
when the patient was first admitted to hospital with symp-
toms, and blood and urine samples could be drawn, and
is not necessarily when the stroke began. Even for the pa-
tients who recovered (those who no longer showed symp-
toms of neurologic deterioration and no further vascular
events), levels of these F2-IsoPs (total, esterified, and ad-
justed for arachidonate) did not decrease completely to the
healthy control range, although some decline was seen
(Fig. 3).
Onset of dengue fever refers to the development of severe
symptoms leading to hospital admission. Dengue fever (on-
set) did not cause any change of esterified F2-IsoPs or total
F2-IsoPs, but interestingly, an increase in plasma free F2-
IsoPs and urinary F2-IsoPs was noted, both of which de-
creased in the recovered patients (Fig. 3). Such change might
be due to possible modification of renal function during the
dengue fever or to changes in lipolysis that could have ac-
celerated the hydrolysis of intact F2-IsoPs esterified to phos-
pholipids (21, 22, 44).
Hydroxyeicosatetraenoic acid products in disease
Total and esterified HETEs levels were found to be about
double the age-matched healthy control level for stroke (on-
set) subjects, even after arachidonate adjustment. At recov-
ery stage, the levels significantly decreased to values similar
to these of the healthy controls (Fig. 4). Free HETEs level did
not change in stroke (Fig. 4).
Onset of dengue fever also was associated with high total
and esterified HETEs, and the total and esterified arachido-
nate-adjusted values compared with the age-matched
healthy control. At the recovery stage, these levels again de-
creased close to the healthy control level. On the contrary,
free HETEs were significantly lower in dengue fever (onset)
group compared with the healthy age-matched controls, and
the level decreased even further on recovery. Elevated lev-
els of total and esterified HETEs and total and esterified
arachidonate-adjusted HETEs in Parkinson’s disease pa-
tients were observed in comparison to the healthy control,
but the free HETEs level did not differ (Fig. 4).
Cholesterol oxidation products in disease
Acute stroke patients had lower 7-hydroxycholesterol
levels compared with the age-matched controls, and these
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TABLE 1. SPEARMAN’S CORRELATION OF BETWEEN PLASMA F2-ISOPROSTANES, ARACHIDONATE, AND AGE
All subjects 50 years 50 years
n r p n r p n r p
Total F2-IsoPs 140 0.21 ns 80 0.23 ns 60 0.24 ns
Esterified F2-IsoPs 140 0.02 ns 80 0.03 ns 60 0.28 ns
Free F2-IsoPs 140 0.06 ns 80 0.11 ns 60 0.01 ns
Arachidonate 81 0.42 0.001 40 0.24 ns 41 0.41 0.01
Total F2-IsoPs/arachidonate 81 0.29 ns 40 0.25 ns 41 0.09 ns
Esterified F2-IsoPs/arachidonate 81 0.16 ns 40 0.19 ns 41 0.02 ns
Gender ratio (malefemale) for all subjects is 11, 50 years is 12 and 50 years is 11.
ns, not significant at 95% confidence interval.
TABLE 2. SPEARMAN’S CORRELATION COEFFICIENT OF BETWEEN PLASMA CHOLESTEROL
OXIDATION PRODUCTS, TOTAL-CHOLESTEROL, AND AGE
All subjects 50 years 50 years
n r p n r p n r p
7-Hydroxycholesterol 95 0.42 0.001 56 0.15 ns 39 0.50 0.010
7-Ketocholesterol 95 0.15 ns 56 0.03 ns 39 0.03 ns
7	-Hydroxycholesterol 95 0.17 ns 56 0.19 ns 39 0.18 ns
24-Hydroxycholesterol 95 0.07 ns 56 0.01 ns 39 0.04 ns
27-Hydroxycholesterol 95 0.39 0.001 56 0.22 ns 39 0.58 0.010
Total-cholesterol 75 0.26 0.050 43 0.19 ns 32 0.67 0.001
7-Hydroxycholesterol/cholesterol 75 0.29 0.050 43 0.29 ns 32 0.06 ns
7-Ketocholesterol/cholesterol 75 0.07 ns 43 0.004 ns 32 0.10 ns
7	-Hydroxycholesterol/cholesterol 75 0.19 ns 43 0.26 ns 32 0.04 ns
24-Hydroxycholesterol/cholesterol 75 0.26 0.050 43 0.16 ns 32 0.42 0.050
27-Hydroxycholesterol/cholesterol 75 0.43 0.001 43 0.54 0.001 32 0.05 ns
Gender ratio (malefemale) for all subjects is 11, 50 years is 11 and 50 years is 11.
ns, not significant at 95% confidence interval.
remained low even at the recovery stage (Fig. 5). However,
it is important to relate these effects to disease-induced
changes in cholesterol levels. After an acute stroke, the total
plasma cholesterol levels tended to be elevated compared
with those of age-matched controls, but at recovery stage,
the levels significantly decreased (Fig. 6). Levels of 7-hy-
droxycholesterol adjusted with cholesterol levels still tended
to be low compared with those of the healthy controls, but
the levels tended to increase after recovery. Other products
of COPs and COPs standardized with total cholesterol were
not affected by stroke (Figs. 5 and 6).
Compared with those in the age-matched healthy controls,
acute dengue fever infection significantly lowered 7-hy-
droxycholesterol, 7-ketocholesterol, 7-hydroxycholesterol,
and 24-hydroxycholesterol levels, whereas at recovery, the
levels increased closer to the levels of age-matched controls
(Fig. 5). However, onset of dengue fever caused markedly
lower cholesterol levels, which increased after recovery. As
a result, 7- and 7-hydroxycholesterol levels adjusted with
total cholesterol were still lower but to a smaller extent, and
7-ketocholesterol and 27-hydroxycholesterol adjusted with
total cholesterol were actually higher than those in the
healthy control (Fig. 6). At the recovery stage of dengue
fever, 7-hydroxycholesterol and 27-hydroxycholesterol ad-
justed with total cholesterol decreased, the latter near to the
levels of the healthy controls (Fig. 6).
Parkinson’s disease subjects showed significantly higher
7-hydroxycholesterol, 7-ketocholesterol, and 27-hydroxyc-
holesterol, but low 24-hydroxycholesterol levels compared
with the healthy controls (Fig. 5). No difference in choles-
terol level was found in Parkinson’s disease compared with
the healthy control, and so adjustment for total cholesterol
also showed significantly high 7-ketocholesterol and 27-hy-
droxycholesterol and low 24-hydroxycholesterol levels com-
pared with those of the healthy controls (Fig. 6).
Discussion
This study showed that different types of diseases (using
examples of two acute diseases and one chronic one) can lead
to altered levels of oxidized lipids. It highlights the advan-
tages of a single methodologic approach for the analysis,
which minimizes the discrepancy of values due to applica-
tion of different analytic methods. Our studies were intended
to observe potential differences in biomarkers of lipid oxi-
dation in different diseases and are not intended at this stage
to investigate the relation of biomarkers to the disease pro-
cess or to propose diagnostic and prognostic assays, espe-
cially given the complex nature of Parkinson’s disease (ef-
fects of various treatments, especially), dengue infection, and
stroke and the wide variations in severity and outcome be-
tween patients. Further detailed studies are being conducted
in larger clinical settings for each disease.
Nevertheless, our data draw attention to several impor-
tant issues when performing any studies of this type. First,
levels of many of the oxidized lipid products are affected by
age, in particular, F2-IsoPs, 7-hydroxycholesterol and 27-
hydroxycholesterol, and the effects vary in different age
bands. The literature contains conflicting reports on the re-
lation of age and F2-IsoPs, where an increase in plasma and
urine was reported (3, 47, 49), a decrease in urine (19), or no
association with age in plasma (10, 25) and in exhaled breath
condensate (29). In our study, healthy controls also showed
an increase in urinary F2-IsoPs with age (25–86 years) but
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FIG. 2. Pearson’s correlation of oxidized lipid products
in plasma of healthy controls (25–86 years). (A) Plasma to-
tal F2-IsoPs vs. arachidonate (n  81). (B) Plasma total F2-
IsoPs vs. urinary F2-IsoPs (n  92). Mean  SEM at 95% con-
fidence level for each correlation is indicated by dotted line.
FIG. 3. Comparison of F2-isoprostane levels between age-matched healthy controls and patients with acute and chronic
diseases. (A) Plasma total F2-IsoPs, (B) plasma esterified F2-IsoPs, (C) plasma free F2-IsoPs, (D) arachidonate, (E) plasma
total F2-IsoPs standardized with arachidonate level, (F) plasma esterified F2-IsoPs standardized with arachidonate level,
and (G) urinary F2-IsoPs. Each graphic column expresses mean  SD. Number of subjects for each disease group is shown
in parentheses. AA, Arachidonate; Cr, creatinine; PD, Parkinson’s disease; DFO, onset of dengue fever; DFR, recovery stage
of dengue fever; STO, onset of ischemic stroke; and STR, recovery stage of ischemic stroke. Unpaired Student’s t tests
showed *p  0.05 and **p  0.01 vs. healthy controls. Repeated analysis of variance showed p  0.05 and p  0.01 be-
tween onset and recovery stages of dengue or ischemic stroke.
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FIG. 4. Comparison of HETEs levels between age-matched healthy controls and patients with acute and chronic
diseases on (A) plasma total HETEs, (B) plasma esterified HETEs, (C) plasma free HETEs, (D) plasma total HETEs
standardized with arachidonate level, and (E) plasma esterified HETEs standardized with arachidonate level. Each
graphic column expresses mean  SD. Number of subjects for each disease group is shown in parentheses. AA, Arachi-
donate; PD, Parkinson’s disease; DFO, onset of dengue fever; DFR, recovery stage of dengue fever; STO, onset of isch-
emic stroke; and STR, recovery stage of ischemic stroke. Unpaired Student’s t test showed *p  0.05 and **p  0.01 vs.
healthy controls. Repeated analysis of variance showed p  0.05 and p  0.01 between onset and recovery stages
of dengue or ischemic stroke.
only in the younger group (25–49 years) and not in the older
group (50–86 years). In contrast, arachidonate, total-choles-
terol, 7-hydroxycholesterol, and 27-hydroxycholesterol de-
creased with age, but more so in subjects older than 50 years
than in those younger than 50 years. One factor might be the
different changes of HDL levels in these groups (8). Hence,
the discrepancies (3, 10, 15, 19, 47, 49) might relate to the use
of different age ranges. It also should be noted that the great
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FIG. 5. Comparison of COPs levels between age-matched healthy controls and patients with acute and chronic dis-
eases. (A) 7-Hydroxycholesterol, (B) 7-ketocholesterol, (C) 7-hydroxycholesterol, (D) 24-hydroxycholesterol, and (E) 27-
hydroxycholesterol. Each graphic column expresses mean  SD. Number of subjects for each disease group is shown in
parentheses. PD, Parkinson’s disease; DFO, onset of dengue fever; DFR, recovery stage of dengue fever; STO, onset of isch-
emic stroke; STR, recovery stage of ischemic stroke. Unpaired Student’s t test showed *p  0.05 and **p  0.01 vs. healthy
controls. Repeated analysis of variance showed p  0.05 between onset and recovery stages of dengue or ischemic stroke.
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FIG. 6. Comparison of total cholesterol and COPs-cholesterol adjusted levels between age-matched healthy 
controls and patients with acute and chronic diseases. (A) Total cholesterol, (B) 7-hydroxycholesterol, (C) 7-ketocholes-
terol, (D) 7-hydroxycholesterol, (E) 24-hydroxycholesterol, and (F) 27-hydroxycholesterol. Each graphic column expresses
as mean  SD. Number of subjects for each disease group is shown in parentheses. PD, Parkinson disease; DFO, onset of
dengue fever; DF,: recovery stage of dengue fever; STO, onset of ischemic stroke; and STR, recovery stage of ischemic stroke.
Unpaired Student’s t test showed *p  0.05 and **p  0.01 vs. healthy controls. Repeated analysis of variance showed p 
0.05 and p  0.01 between onset and recovery stages of dengue.
majority of our patients are of Chinese origin (in Singapore),
whereas previous studies examined United States and Eu-
ropean populations. Whether this affects the results remains
uncertain.
Our second conclusion is that diseases do not show ele-
vations in all lipid oxidation products (i.e., disease itself does
not simply elevate all biomarkers of oxidative lipid damage).
Thus, for F2-IsoPs, we saw an increase in stroke but not in
dengue or Parkinson’s disease, and for COPs in Parkinson’s
disease but not in stroke. By contrast, elevated HETEs were
found in all three diseases (discussed later). It is well known
that free radicals play a role in lipid peroxidation involved
in human ischemia/reperfusion injury (14, 15, 23). It was re-
ported that F2-IsoPs levels were elevated within the first 8 h
of stroke (20), but in our study, high levels were still recorded
within 24 h of stroke and tended to decrease on recovery
(day 7) in patients who recovered. This was clearly shown
in ischemic-stroke patients in whom the levels of F2-IsoPs
were elevated (20, 46). Oxidized lipid compounds, in partic-
ular F2-IsoPs, have been linked to vascular function, whereas
an increase is often related to vasoconstriction (25).
Our investigation showed plasma F2-IsoPs were not el-
evated in Parkinson’s disease compared with the age-
matched study controls. F2-IsoPs have been previously
measure in the substantia nigra (27) in Parkinson’s disease
patients, but the levels were not elevated, although those
of isofurans were. A relation was found between urinary
F2-IsoPs and plasma free F2-IsoPs in Parkinson’s disease
in this study but not in age-matched healthy controls.
However, a strong correlation (Fig. 4) between total F2-
IsoPs and urinary F2-IsoPs in our total population of
healthy controls (25–86 years) was found, and it appears
to be attributed to the younger population, those younger
than 50 years (25–49 years; r  0.34; p  0.01) and not
older than 50 years (50–86 years; r  0.18; p  0.15). Our
results in healthy subjects are consistent with those of
Morrow et al. (31). The difference for Parkinson’s disease
is unknown, although it could be related to altered renal
function or excessive production of local free F2-IsoPs in
the kidney (21, 38, 44). Our results also indicate the need
to consider whether in disease, we should measure plasma
F2-IsoPs, urinary F2-IsoPs, or both, as done here. Another
interesting point is that both plasma total (r  0.52) and
urinary (r  0.41) F2-IsoPs levels tended to increase with
age in the Parkinson’s disease group but not in normal
controls, perhaps suggesting that the longer one has
Parkinson’s disease, the more oxidative stress may tend
to increase.
It was initially surprising to find that COPs levels in stroke
patients were not elevated compared with those in the
healthy group, in particular, 24-hydroxycholesterol, which is
known to arise from brain (5). A similar report has been
made (6), and it was concluded that a limit exists in mea-
suring 24-hydroxycholesterol in plasma of stroke patients be-
cause of damaged regulation of the enzyme 24-hydroxylase
(17). Our data also reveal the potential confounding effects
of changes in cholesterol levels during stroke (perhaps af-
fected by changes in nutrient intake, disordered lipid me-
tabolism, or changes in the use of cholesterol-lowering
drugs). In intracerebral metabolism of the blood–brain bar-
rier in humans, where 27-hydroxycholesterol passes into the
brain and 24-hydroxycholesterol out of the brain, the con-
centration gradient created modifies the metabolism in the
liver and the brain (4, 16). Thus a ratio of 27-hydoxycholes-
terol/24-hydroxycholesterol is often expressed in disease
models. It is suggested the ratio of 27-hydroxycholes-
terol/24-hydroxycholesterol is about 0.2 in brain and about
2 in circulation; this demonstrates the abnormality of cho-
lesterol homeostasis in stroke in this study, where a ratio of
0.7 was recorded in plasma. Moreover, the ratio of 27-hy-
doxycholesterol/24-hydroxycholesterol is quoted to be high
in the brain of neurologic disease patients (4, 16). We found
it to be sixfold higher in the plasma of Parkinson’s disease
patients compared with the healthy group in our study.
High 7-ketocholesterol and 27-hydroxycholesterol, and
low 24-hydroxycholesterol, even when normalized by cho-
lesterol levels in Parkinson’s disease, indicate the complex-
ity of the changes in this disease. The high level of 7-hy-
droxycholesterol in Parkinson’s disease may indicate not
only involvement of free radical reactions on cholesterol but
also the 27-hydroxylase enzymes that produce 27-hydroxy-
cholesterol (4), which could further break down to produce
7-ketocholesterol and 7-hydroxycholesterol (18). Further, in
the pathogenesis of neurologic disorders, it appears that
plasma 24-hydroxycholesterol decreases with age, also cor-
responding to the size of the brain and loss of hepatic func-
tion (6).
It is suggested that lipid oxidation products may have in-
flammatory potency in certain diseases, although sometimes
antiinflammatory effects have been described (2, 32, 40). The
pathology of dengue fever patients involves intense inflam-
mation and depression of platelet levels. These changes are
linked to altered cytokines, immune function, lipid metabo-
lism, and nutrition and may lead to low total cholesterol and
COPs level in dengue fever (36, 45).
Interestingly, HETEs were elevated in Parkinson’s dis-
ease, dengue fever, and stroke. HETEs are oxidized prod-
ucts of arachidonic acid via enzymatic reaction of cy-
tochrome P450, hydroxylases, and lipoxygenases, or by
free radical reactions. Like F2-IsoPs, numerous isomers of
HETEs exist, and individual isomers were not determined
in our study (22). Moreover, production of 20-HETE is sug-
gested to be induced in ischemia/reperfusion injury (11,
12, 13, 34) and to lead to vasoconstriction, especially in
small arteries (39). 20-HETE is also known to mediate vaso-
constriction in cerebral vascular function, and regulation
of renal vascular tone and maintenance of renal blood flow
(39, 52, 53). Thus, the elevated levels in stroke revealed in
this study are potentially deleterious. Conversely, 5-, 8-,
12-, and 15-HETEs (which are constituents of the total
HETEs measured in this study) are produced by nonen-
zymatic free-radical–mediated peroxidation of arachidonic
acid (51). High levels were recorded in human atheroscle-
rotic plaques (24), and HETEs may be associated with tu-
mor development (35). Further, increases in plasma 9-
HETE have been associated with increased risk of coronary
artery disease (41), and 15-HETE increase is related to cere-
bral vasoconstriction (11).
These data illustrate our third major conclusion in mea-
suring biomarkers of oxidized lipids in clinical samples; it is
essential to present data for oxidized lipids not only per mil-
liliter of plasma but also per unit substrate. This is reflected
in dengue fever patients, in whom plasma total F2-IsoPs were
the same between onset and recovery stage when expressed
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per milliliter plasma, but the levels at recovery stage were
lower than those at the onset stage when expressed per mi-
crogram of arachidonate. Such observations were also made
in COPs of dengue fever patients, in whom levels expressed
per milliliter plasma showed higher 7- and 7-hydroxyc-
holesterol levels in the recovery stage of dengue fever, but
the opposite effect was found when expressed per milligram
total cholesterol.
Finally, we conclude that to assess oxidized lipid damage
products accurately in human diseases (or at least for Parkin-
son’s disease, dengue fever, and stroke), we must examine
several biomarkers, and the methods used in this study may
have value in this respect.
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